Abstract 346P
Background
Chemotherapy-induced neutropenia (CIN) is a main side effect in chemotherapy of breast cancer (BC) patients. It may lead to febrile neutropenia that requires hospitalization and antibiotic treatment resulting in increased cost and unfavourable outcome. Little is known about the incidence of CIN in Indonesia despite the fact that BC is the most prevalent malignancy. This study investigates the occurence of severe CIN and identify its associated risk factors.
Methods
We considered 123 newly-diagnosed BC patients without terminal conditions and multiple cormobidities from July 2018 to July 2019. All patients received a three-weekly adjuvant, neo-adjuvant, or palliative chemotherapy without primary prophylaxis of GCSF. We defined severe CIN as the condition where absolute neutrophil count <0.5x109/L during any chemotherapy cycle. We evaluated the association of clinical, pathological, and treatment factors with the risk of CIN in a logistic regression methodology, adjusted for patients’ demography.
Results
In this cohort, 73% patients had experienced severe CIN at least once during their chemotherapy. The risk of severe CIN in the 2nd, 3rd, and 4th cycle did not differ from the 1st cycle. However, after the 5th cycle, the risk significantly increased (p values ≤ 0.001 up to the 8th cycle). Higher age, poor ECOG index, lower pre-treatment monocyte count, and palliative intention were associated with the increased risk of severe CIN, while diabetes comorbidity was associated with the decreased risk (p= 0.049, < 0.001, 0.022, 0.037, and 0.017, respectively).
Conclusions
We have identified some risk factors for increasing the risk of severe CIN. These factors can serve as a guidance to support care and recognize those at high risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The Indonesian Ministry of Research, Technology, and Higher Education.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session
211P - The impact of low muscle mass to overall survival in bladder cancer patients undergoing chemotherapy: A systematic review and meta-analysis
Presenter: Karunia Japar
Session: e-Poster Display Session
212P - Stage I non-seminoma testicular cancer: Adjuvant management and outcomes
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
213P - Stage I seminoma testicular cancer: Predictors of relapse and outcomes for adjuvant carboplatin vs active surveillance
Presenter: Gaik Tin Quah
Session: e-Poster Display Session
214P - Study of treatment outcome in adults with TFE related RCC
Presenter: Ajaykumar Singh
Session: e-Poster Display Session
215P - Analysis of spatial heterogeneity of responses in metastatic sites with nivolumab in renal cell carcinoma
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
216P - Clinical profile and treatment outcome of testicular seminoma treated at tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
220P - A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer
Presenter: Winnie Sung
Session: e-Poster Display Session
221P - Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo (PBO) and ongoing androgen deprivation therapy (ADT) in SPARTAN
Presenter: Hiroji Uemura
Session: e-Poster Display Session
222P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Matthew R. Smith
Session: e-Poster Display Session